Public dataset
Recorded source agreement and disagreement
Show whether sources print one normalized reading, have incompatible units, lack structured comparison context, or contain a context-matched numeric difference.
- Public rows
- 1,681
- Generated
- Schema version
- source-consensus/2
Coverage
What this run contains
- Compared medicine fields
- 1,681
- Agree
- 1,282
- Differ
- 0
- Not comparable
- 12
- Insufficient context
- 387
- Fields represented
- 5
- bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
Method
How the rows were made
- Deterministic rules normalize recorded pharmacokinetic readings and compare only like-for-like values.
- One normalized printed reading may be agree even when clinical context was not extracted; this reports printed-reading agreement only.
- Distinct readings may differ only when their units and denominators are comparable and one matching, non-placeholder population/formulation context was structurally extracted. Otherwise they are insufficient_context.
- not_comparable preserves incompatible units or denominators instead of guessing. insufficient_context preserves missing or non-matching structured context instead of manufacturing agreement or disagreement.
- The agreement rate describes the distribution of recorded source readings; it is not a probability that a value is true.
- Every distinct printed reading retains its unit, population context, source count, and complete source records. The API paginates field rows, never child readings or sources.
- documentsExamined is every matching single-substance archive document inspected for that medicine. The generator has no document, reading, or source ceiling, so there is no hidden available-versus-retained remainder.
Limits
Read these before using a row
- Current label parsing does not structurally extract population or formulation context. Distinct otherwise-comparable readings are therefore insufficient_context, never differ; agree may mean printed-reading agreement only. Source records are complete but are not independent-experiment counts.
- The current deterministic parser does not structurally extract population or formulation context from these sentences. It records that context as unknown and cannot publish distinct same-unit readings as differ.
- Neither reading is marked wrong. Population, formulation, route, and other unextracted context may explain the printed difference.
- Only the recorded fields and source documents in this snapshot are compared.
- A source count is the number of retained source records in the row, not a count of independent experiments.
Provenance
Source examples
abacavir · bioavailability · agree
15 documents examined; 83% (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)The geometric mean absolute bioavailability of the tablet was 83%.
alemtuzumab · volumeOfDistribution · not_comparable
2 documents examined; 0.18 L/kg (Unknown: population and formulation context were not structurally extracted from this source sentence.); 14.1 L (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:4f5f7255-7abc-4328-bd1a-ceaf139ef3e0 (opens source in a new tab)Distribution After the last 30 mg dose, the mean volume of distribution at steady-state was 0.18 L/kg (range 0.1 to 0.4 L/kg).
abiraterone · halfLife · insufficient_context
31 documents examined; 12 ± 5 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.); 18 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:c9eb9b46-f847-40a8-802c-a51b40406d5a (opens source in a new tab)Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.
Artifact used for this view: data/source-consensus.ndjson. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.
Schema
Fields in the public projection
| Field | Type | Meaning |
|---|---|---|
| medicineSlug | string | Stable RNAWiki medicine route key. |
| field | string | Recorded pharmacokinetic field being compared. |
| comparisonState | string | agree (printed-reading agreement), differ (context-matched comparable disjoint values), not_comparable (unit/denominator mismatch), or insufficient_context. Every state remains declared even when its current count is zero. |
| comparisonReasons | string[] | Deterministic codes explaining the state. |
| documentsExamined | number | Recorded source documents considered for the field. |
| sourceCount | number | Recorded source readings represented. |
| agreementRate | number | Share represented by the leading normalized printed-reading group; not a confidence score or clinical agreement probability. |
| readings | consensus-reading[] | Complete, untruncated reading groups. Each keeps the printed display, numeric value when parsed, unit, population context, source count, and every source identity, version/effective date or explicit absence, retrieval date, locator, safe link, and excerpt. |
Reader
Search and filter the rows
Showing 1,051–1,060 of 1,681 matching rows. Filters and search terms remain attached when you move between pages or open the API view.
Projected row 1051
- Medicine slug
- nafcillin
- Compared field
- proteinBinding
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 17
- Source count
- 17
- Agreement rate
- 0.764706
- Recorded readings
89.9 ± 1.5%
- Numeric value
- 89.9
- Unit
- %
- Source records
- 13
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 13 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0f21384c-0f82-4d99-a05c-6773d1ee4bcf (opens source in a new tab)
Nafcillin label
Version not recorded · Effective date not recorded
The degree of protein binding reported for nafcillin is 89.9 ± 1.5%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:90717878-64cb-4ffc-90bc-7b4e81e3d1cd (opens source in a new tab)
Nafcillin label
Version not recorded · Effective date not recorded
The degree of protein binding reported for nafcillin is 89.9 ± 1.5%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bbf0d8e4-b8e4-4958-b6b6-f0b9960f3b6a (opens source in a new tab)
Nafcillin label
Version not recorded · Effective date not recorded
The degree of protein binding reported for nafcillin is 89.9 ± 1.5%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:34821770-929c-40ea-a9e4-d4405dc869e1 (opens source in a new tab)
Nafcillin label
Version not recorded · Effective date not recorded
The degree of protein binding reported for nafcillin is 89.9 ± 1.5%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:77999cd2-17b8-4df9-b687-d0f9b62096b9 (opens source in a new tab)
Nafcillin label
Version not recorded · Effective date not recorded
The degree of protein binding reported for nafcillin is 89.9 ± 1.5%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ae5fb012-4012-4063-b2e4-f1f927c6bf74 (opens source in a new tab)
Nafcillin label
Version not recorded · Effective date not recorded
The degree of protein binding reported for nafcillin is 89.9 ± 1.5%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:91ebf84a-310f-4271-8446-5a10a877883a (opens source in a new tab)
Nafcillin label
Version not recorded · Effective date not recorded
The degree of protein binding reported for nafcillin is 89.9 ± 1.5%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a6a4e122-b7f5-4eb5-8555-7aea6eda794b (opens source in a new tab)
Nafcillin label
Version not recorded · Effective date not recorded
The degree of protein binding reported for nafcillin is 89.9 ± 1.5%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8ec288e6-4d7f-4fea-a5ab-f9f337ebaa86 (opens source in a new tab)
Nafcillin label
Version not recorded · Effective date not recorded
The degree of protein binding reported for nafcillin is 89.9 ± 1.5%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cd2d18c5-95a2-4fb4-bd8b-b5d39e2da416 (opens source in a new tab)
Nafcillin label
Version not recorded · Effective date not recorded
The degree of protein binding reported for nafcillin is 89.9 ± 1.5%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c39721a3-7b22-4720-9dbd-bc82f03d2af7 (opens source in a new tab)
Nafcillin label
Version not recorded · Effective date not recorded
The degree of protein binding reported for nafcillin is 89.9 ± 1.5%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3c2581a1-8051-4d7a-a1f7-521248648dc9 (opens source in a new tab)
Nafcillin label
Version not recorded · Effective date not recorded
The degree of protein binding reported for nafcillin is 89.9 ± 1.5%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0556378a-b794-4235-ba09-ebdc295e9092 (opens source in a new tab)
Nafcillin label
Version not recorded · Effective date not recorded
The degree of protein binding reported for nafcillin is 89.9 ± 1.5%.
89.9 +/-1.5%
- Numeric value
- 89.9
- Unit
- %
- Source records
- 4
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 4 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4b3b8e52-df96-4886-e063-6294a90ac63f (opens source in a new tab)
Nafcillin label
Version not recorded · Effective date not recorded
The degree of protein binding reported has been 89.9 +/-1.5%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8a00624c-c436-4102-a042-dab54022bcc2 (opens source in a new tab)
Nafcillin label
Version not recorded · Effective date not recorded
The degree of protein binding reported has been 89.9 +/-1.5%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4d3b0076-3780-413f-9052-b23be5f18f01 (opens source in a new tab)
Nafcillin label
Version not recorded · Effective date not recorded
The degree of protein binding reported has been 89.9 +/-1.5%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:090fda61-b9c8-640e-e063-6294a90a7363 (opens source in a new tab)
Nafcillin label
Version not recorded · Effective date not recorded
The degree of protein binding reported has been 89.9 +/-1.5%.
Projected row 1052
- Medicine slug
- naftifine
- Compared field
- tMax
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 5
- Source count
- 4
- Agreement rate
- 0.5
- Recorded readings
20.0 hours
- Numeric value
- 20
- Unit
- hours
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6c6ee055-4031-45a7-8561-ccd989343580 (opens source in a new tab)
Naftifine label
Version not recorded · Effective date not recorded
Median T max was 20.0 hours (range: 8, 20 hours) after a single application on Day 1 and 8.0 hours (range: 0, 24 hours) on Day 14.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6645994a-ecb3-277b-e053-2a91aa0a81e5 (opens source in a new tab)
Naftifine label
Version not recorded · Effective date not recorded
Median T max was 20.0 hours (range: 8, 20 hours) after a single application on Day 1 and 8.0 hours (range: 0, 24 hours) on Day 14.
20 hours
- Numeric value
- 20
- Unit
- hours
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:92d3ec30-2176-49cd-8a70-668ef65e7663 (opens source in a new tab)
Naftifine label
Version not recorded · Effective date not recorded
Median T max was 20 hours (range: 8, 20 hours) after a single application on Day 1 and 8 hours (range: 0, 24 hours) on Day 14.
8 hours
- Numeric value
- 8
- Unit
- hours
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a740fc0d-45b3-411f-9dfd-f3d637b8a95f (opens source in a new tab)
Naftifine label
Version not recorded · Effective date not recorded
Median time to C max (T max ) was 8 hours (range: 4 to 24 hours) on Day 1 and 6 hours (range: 0 to 16 hours) on Day 14.
Projected row 1053
- Medicine slug
- nalbuphine
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 11
- Source count
- 11
- Agreement rate
- 1
- Recorded readings
5 hours
- Numeric value
- 5
- Unit
- hours
- Source records
- 11
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 11 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dd621bfa-ce48-4c27-b247-a6d885f70b72 (opens source in a new tab)
Nalbuphine label
Version not recorded · Effective date not recorded
The plasma half-life of nalbuphine is 5 hours, and in clinical studies the duration of analgesic activity has been reported to range from 3 to 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:28f274a4-62c4-4e54-e063-6394a90a2200 (opens source in a new tab)
Nalbuphine label
Version not recorded · Effective date not recorded
The plasma half-life of nalbuphine is 5 hours, and in clinical studies the duration of analgesic activity has been reported to range from 3 to 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:596826ff-e471-4d4f-9a73-2a34e2af2dd6 (opens source in a new tab)
Nalbuphine label
Version not recorded · Effective date not recorded
The plasma half-life of nalbuphine is 5 hours, and in clinical studies the duration of analgesic activity has been reported to range from 3 to 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6bde2184-5643-3ec6-e053-2991aa0a115f (opens source in a new tab)
Nalbuphine label
Version not recorded · Effective date not recorded
The plasma half-life of nalbuphine is 5 hours, and in clinical studies the duration of analgesic activity has been reported to range from 3 to 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6025e8d4-5083-4c3a-58a0-050e7b0b6150 (opens source in a new tab)
Nalbuphine label
Version not recorded · Effective date not recorded
The plasma half-life of nalbuphine is 5 hours, and in clinical studies the duration of analgesic activity has been reported to range from 3 to 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a99fe500-f52b-483c-807c-178f1a78a02b (opens source in a new tab)
Nalbuphine label
Version not recorded · Effective date not recorded
The plasma half-life of nalbuphine is 5 hours, and in clinical studies the duration of analgesic activity has been reported to range from 3 to 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d82dafac-cce7-445a-8127-2a10b6d947ca (opens source in a new tab)
Nalbuphine label
Version not recorded · Effective date not recorded
The plasma half-life of nalbuphine is 5 hours, and in clinical studies the duration of analgesic activity has been reported to range from 3 to 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:292b0d0e-f222-d384-e063-6394a90acd44 (opens source in a new tab)
Nalbuphine label
Version not recorded · Effective date not recorded
The plasma half-life of nalbuphine is 5 hours, and in clinical studies the duration of analgesic activity has been reported to range from 3 to 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:38569b5f-fb37-135e-e063-6294a90a54df (opens source in a new tab)
Nalbuphine label
Version not recorded · Effective date not recorded
The plasma half-life of nalbuphine is 5 hours, and in clinical studies the duration of analgesic activity has been reported to range from 3 to 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4ef2c0dc-3ab4-4bb1-aff0-523e3c23ad2d (opens source in a new tab)
Nalbuphine label
Version not recorded · Effective date not recorded
The plasma half-life of nalbuphine is 5 hours, and in clinical studies the duration of analgesic activity has been reported to range from 3 to 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a3221c05-5822-4ab8-b589-0e3939b91a68 (opens source in a new tab)
Nalbuphine label
Version not recorded · Effective date not recorded
The plasma half-life of nalbuphine is 5 hours, and in clinical studies the duration of analgesic activity has been reported to range from 3 to 6 hours.
Projected row 1054
- Medicine slug
- nalmefene
- Compared field
- halfLife
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 4
- Source count
- 3
- Agreement rate
- 0.666667
- Recorded readings
10.8 ± 5.2 hours
- Numeric value
- 10.8
- Unit
- hours
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:22d67228-6c24-47ca-afc7-52ef279520a0 (opens source in a new tab)
Nalmefene label
Version not recorded · Effective date not recorded
ELIMINATION After intravenous administration of 1 mg nalmefene hydrochloride injection to normal males (ages 19-32), plasma concentrations declined biexponentially with a redistribution and a terminal elimination half-life of 41 ± 34 minutes and 10.8 ± 5.2 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3abfbffc-9e52-4fc6-ae92-6e0a97f4afe7 (opens source in a new tab)
Nalmefene label
Version not recorded · Effective date not recorded
ELIMINATION After intravenous administration of 1 mg nalmefene hydrochloride injection to normal males (ages 19 to 32), plasma concentrations declined biexponentially with a redistribution and a terminal elimination half-life of 41 ± 34 minutes and 10.8 ± 5.2 hours, respectively.
10.2 ± 2.2 hours
- Numeric value
- 10.2
- Unit
- hours
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a59a5847-9fe4-4341-a203-be0a5e6d3e36 (opens source in a new tab)
Nalmefene label
Version not recorded · Effective date not recorded
The elimination half-life was prolonged in ESRD patients from 10.2 ± 2.2 hours in normal patients to 26.1 ± 9.9 hours.
Projected row 1055
- Medicine slug
- nalmefene
- Compared field
- tMax
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 4
- Source count
- 2
- Agreement rate
- 1
- Recorded readings
0.250 hours
- Numeric value
- 0.25
- Unit
- hours
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a59a5847-9fe4-4341-a203-be0a5e6d3e36 (opens source in a new tab)
Nalmefene label
Version not recorded · Effective date not recorded
.5 mg ZURNAI Intramuscular (IM), 1.0 mg Nalmefene IM, and 1.0 mg Nalmefene Intravenous (IV) (a) (b) Absorption After administration of one ZURNAI to healthy adult subjects, the median T max for ZURNAI was 0.250 hours, compared to 0.5 hours for the intramuscular nalmefene 1 mg injection.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:999a4269-9e54-4801-b2ac-2a7276f0b94f (opens source in a new tab)
Nalmefene label
Version not recorded · Effective date not recorded
prays in One Nostril) (a) (b) Figure 3 (a) Figure 3 (b) Figure 4 (a) Figure 4 (b) Absorption After administration of one 2.7 mg OPVEE nasal spray to healthy adult subjects, the median T max for OPVEE was 0.250 hours, compared to 0.33 hours for the intramuscular nalmefene.
Projected row 1056
- Medicine slug
- nalmefene
- Compared field
- volumeOfDistribution
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 4
- Source count
- 3
- Agreement rate
- 1
- Recorded readings
3.9 ± 1.1 L/kg
- Numeric value
- 3.9
- Unit
- L/kg
- Source records
- 3
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 3 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a59a5847-9fe4-4341-a203-be0a5e6d3e36 (opens source in a new tab)
Nalmefene label
Version not recorded · Effective date not recorded
There was an apparent age-related decrease in the central volume of distribution (young: 3.9 ± 1.1 L/kg, elderly: 2.8 ± 1.1 L/kg) that resulted in a greater initial nalmefene concentration in the elderly group.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:22d67228-6c24-47ca-afc7-52ef279520a0 (opens source in a new tab)
Nalmefene label
Version not recorded · Effective date not recorded
There was an apparent age-related decrease in the central volume of distribution (young: 3.9 ± 1.1 L/kg, elderly: 2.8 ± 1.1 L/kg) that resulted in a greater initial nalmefene concentration in the elderly group.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3abfbffc-9e52-4fc6-ae92-6e0a97f4afe7 (opens source in a new tab)
Nalmefene label
Version not recorded · Effective date not recorded
There was an apparent age-related decrease in the central volume of distribution (young: 3.9 ± 1.1 L/kg, elderly: 2.8 ± 1.1 L/kg) that resulted in a greater initial nalmefene concentration in the elderly group.
Projected row 1057
- Medicine slug
- naloxone
- Compared field
- halfLife
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 79
- Source count
- 57
- Agreement rate
- 0.842105
- Recorded readings
3.1 ± 0.5 hours
- Numeric value
- 3.1
- Unit
- hours
- Source records
- 48
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 48 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4d66b96a-acbb-2292-e063-6294a90af788 (opens source in a new tab)
Naloxone label
Version not recorded · Effective date not recorded
In a neonatal study, the mean plasma half-life was observed to be 3.1 ± 0.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:201fdedf-1736-4e52-9d7d-de14292547fd (opens source in a new tab)
Naloxone label
Version not recorded · Effective date not recorded
In a neonatal study the mean plasma half-life was observed to be 3.1 ± 0.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b621239f-0bbb-7d07-e053-2a95a90a287e (opens source in a new tab)
Naloxone label
Version not recorded · Effective date not recorded
In a neonatal study the mean plasma half-life was observed to be 3.1 ± 0.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d2f5bfa0-933e-46d0-8b1a-9f90e6aaba54 (opens source in a new tab)
Naloxone label
Version not recorded · Effective date not recorded
In a neonatal study the mean plasma half-life was observed to be 3.1 ± 0.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d96ebf2e-1051-4b5b-b1c6-2543dbbb2d04 (opens source in a new tab)
Naloxone label
Version not recorded · Effective date not recorded
In a neonatal study the mean plasma half-life was observed to be 3.1 ± 0.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3f2bb95a-aeca-c0b7-e063-6394a90a627b (opens source in a new tab)
Naloxone label
Version not recorded · Effective date not recorded
In a neonatal study, the mean plasma half-life was observed to be 3.1 ± 0.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7faaedb3-227b-408d-b772-6b326638b00e (opens source in a new tab)
Naloxone label
Version not recorded · Effective date not recorded
In a neonatal study the mean plasma half-life was observed to be 3.1 ± 0.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:53ed164c-dd09-4ea4-e063-6294a90a2434 (opens source in a new tab)
Naloxone label
Version not recorded · Effective date not recorded
In a neonatal study the mean plasma half-life was observed to be 3.1 ± 0.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9bcff682-1196-7cef-e053-2a95a90aa954 (opens source in a new tab)
Naloxone label
Version not recorded · Effective date not recorded
In a neonatal study, the mean plasma half-life was observed to be 3.1 ± 0.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3ba53405-5e72-c035-e063-6294a90ac0b1 (opens source in a new tab)
Naloxone label
Version not recorded · Effective date not recorded
In a neonatal study, the mean plasma half-life was observed to be 3.1 ± 0.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2879294f-9af9-459e-e063-6394a90a0820 (opens source in a new tab)
Naloxone label
Version not recorded · Effective date not recorded
In a neonatal study, the mean plasma half-life was observed to be 3.1 ± 0.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9e53f169-4a6e-6102-e053-2995a90ab3dc (opens source in a new tab)
Naloxone label
Version not recorded · Effective date not recorded
In a neonatal study, the mean plasma half-life was observed to be 3.1 ± 0.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c7fa8d4f-28a7-4ef5-aef8-cbd4328ce599 (opens source in a new tab)
Naloxone label
Version not recorded · Effective date not recorded
In a neonatal study the mean plasma half-life was observed to be 3.1 ± 0.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2725b9c0-5b1e-498b-9ec5-ee76a62e656a (opens source in a new tab)
Naloxone label
Version not recorded · Effective date not recorded
In a neonatal study the mean plasma half-life was observed to be 3.1 ± 0.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:28f3e3bc-b1be-9f06-e063-6394a90a1936 (opens source in a new tab)
Naloxone label
Version not recorded · Effective date not recorded
In a neonatal study, the mean plasma half-life was observed to be 3.1 ± 0.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:48137634-91d7-41e3-b54b-e4321d69668a (opens source in a new tab)
Naloxone label
Version not recorded · Effective date not recorded
In a neonatal study the mean plasma half-life was observed to be 3.1 ± 0.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ebf0f833-c1c0-487c-8f29-01fa8c61b6cb (opens source in a new tab)
Naloxone label
Version not recorded · Effective date not recorded
In a neonatal study of naloxone hydrochloride the mean (±SD) plasma half-life was observed to be 3.1 ± 0.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3ae08e26-223b-4971-b2f1-f1e183a3f930 (opens source in a new tab)
Naloxone label
Version not recorded · Effective date not recorded
In a neonatal study the mean plasma half-life was observed to be 3.1 ± 0.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ada6856c-5293-fc2f-e053-2995a90a8ec6 (opens source in a new tab)
Naloxone label
Version not recorded · Effective date not recorded
In a neonatal study the mean plasma half-life was observed to be 3.1 ± 0.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b59ee3cc-9604-4abc-81be-897e2f42aa67 (opens source in a new tab)
Naloxone label
Version not recorded · Effective date not recorded
In a neonatal study, the mean plasma half-life was observed to be 3.1 ± 0.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ef647e2a-84e7-4e3e-942a-b6fc250141b6 (opens source in a new tab)
Naloxone label
Version not recorded · Effective date not recorded
In a neonatal study the mean plasma half-life was observed to be 3.1 ± 0.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:236349ef-2cb5-47ca-a3a5-99534c3a4996 (opens source in a new tab)
Naloxone label
Version not recorded · Effective date not recorded
In a neonatal study the mean plasma half-life was observed to be 3.1 ± 0.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dfa48492-d83b-48cc-9ad1-bdc0c2ac9931 (opens source in a new tab)
Naloxone label
Version not recorded · Effective date not recorded
In a neonatal study, the mean plasma half-life was observed to be 3.1 ± 0.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3856ea66-29b8-8fc2-e063-6394a90ac33a (opens source in a new tab)
Naloxone label
Version not recorded · Effective date not recorded
In a neonatal study, the mean plasma half-life was observed to be 3.1 ± 0.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:94ff1857-06da-7986-e053-2a95a90afb18 (opens source in a new tab)
Naloxone label
Version not recorded · Effective date not recorded
In a neonatal study, the mean plasma half-life was observed to be 3.1 ± 0.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ea4ea2fe-af48-0b3c-e053-2a95a90a0ad5 (opens source in a new tab)
Naloxone label
Version not recorded · Effective date not recorded
In a neonatal study the mean plasma half-life was observed to be 3.1 ± 0.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f9c5efca-443a-41a0-e053-6294a90a8774 (opens source in a new tab)
Naloxone label
Version not recorded · Effective date not recorded
In a neonatal study the mean plasma half-life was observed to be 3.1 ± 0.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3d2dcee4-7510-477b-95a8-9b2afb773984 (opens source in a new tab)
Naloxone label
Version not recorded · Effective date not recorded
In a neonatal study the mean plasma half-life was observed to be 3.1 ± 0.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d4c44b74-4e36-4b63-80eb-64ce99ccb39f (opens source in a new tab)
Naloxone label
Version not recorded · Effective date not recorded
In a neonatal study the mean plasma half-life was observed to be 3.1 ± 0.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8bcf426a-b4fc-4f24-9ad0-fb26168a0b56 (opens source in a new tab)
Naloxone label
Version not recorded · Effective date not recorded
In a neonatal study the mean plasma half-life was observed to be 3.1 ± 0.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f0932877-1f3b-4d5e-82d2-dd6c53db4730 (opens source in a new tab)
Naloxone label
Version not recorded · Effective date not recorded
In a neonatal study the mean plasma half-life was observed to be 3.1 ± 0.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:74fc593e-ed47-efae-e053-2991aa0a5997 (opens source in a new tab)
Naloxone label
Version not recorded · Effective date not recorded
In a neonatal study the mean plasma half-life was observed to be 3.1 ± 0.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e65e03c1-9a66-b30b-e053-2995a90aeb73 (opens source in a new tab)
Naloxone label
Version not recorded · Effective date not recorded
In a neonatal study the mean plasma half-life was observed to be 3.1 ± 0.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d39635a4-ddb3-4d32-8211-eb84c78e9f59 (opens source in a new tab)
Naloxone label
Version not recorded · Effective date not recorded
In a neonatal study, the mean plasma half-life was observed to be 3.1 ± 0.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3d8813be-6d22-46f1-ac25-0d8a817a521c (opens source in a new tab)
Naloxone label
Version not recorded · Effective date not recorded
In a neonatal study the mean plasma half-life was observed to be 3.1 ± 0.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bd65e3fe-cd7a-4855-8f55-8cc3a0921ccc (opens source in a new tab)
Naloxone label
Version not recorded · Effective date not recorded
In a neonatal study the mean plasma half-life was observed to be 3.1 ± 0.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b1303f15-c48b-a44d-b28a-72f370094e02 (opens source in a new tab)
Naloxone label
Version not recorded · Effective date not recorded
In a neonatal study the mean plasma half-life was observed to be 3.1 ± 0.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c72a60fb-196d-3f02-e053-2995a90ad906 (opens source in a new tab)
Naloxone label
Version not recorded · Effective date not recorded
In a neonatal study the mean plasma half-life was observed to be 3.1 ± 0.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c90e2d85-ed94-2c00-e053-2a95a90ad2a0 (opens source in a new tab)
Naloxone label
Version not recorded · Effective date not recorded
In a neonatal study the mean plasma half-life was observed to be 3.1 ± 0.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5906381c-81f4-4635-867a-e56e4d629692 (opens source in a new tab)
Naloxone label
Version not recorded · Effective date not recorded
In a neonatal study, the mean plasma half-life was observed to be 3.1 ± 0.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:68df290c-d776-4cfc-9565-332eb56c4723 (opens source in a new tab)
Naloxone label
Version not recorded · Effective date not recorded
In a neonatal study the mean plasma half-life was observed to be 3.1 ± 0.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d04ae2d7-01b9-405d-bb7a-bf2d876ce26a (opens source in a new tab)
Naloxone label
Version not recorded · Effective date not recorded
In a neonatal study the mean plasma half-life was observed to be 3.1 ± 0.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:aef6719c-cd71-46ee-b7b1-1806b939bf3e (opens source in a new tab)
Naloxone label
Version not recorded · Effective date not recorded
In a neonatal study the mean plasma half-life was observed to be 3.1 ± 0.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ddeebc32-9aab-4a2f-8c87-74335d17d5ef (opens source in a new tab)
Naloxone label
Version not recorded · Effective date not recorded
In a neonatal study the mean plasma half-life was observed to be 3.1 ± 0.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fa1ca55b-f56b-0d9b-e053-6294a90a258a (opens source in a new tab)
Naloxone label
Version not recorded · Effective date not recorded
In a neonatal study the mean plasma half-life was observed to be 3.1 ± 0.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:74fcd243-94b3-ec77-e053-2991aa0a229c (opens source in a new tab)
Naloxone label
Version not recorded · Effective date not recorded
In a neonatal study, the mean plasma half-life was observed to be 3.1 ± 0.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:958577c3-d2c4-26ad-e053-2a95a90ad73a (opens source in a new tab)
Naloxone label
Version not recorded · Effective date not recorded
In a neonatal study the mean plasma half-life was observed to be 3.1 ± 0.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5de44ee7-6525-4857-9a67-8882e96dbeb5 (opens source in a new tab)
Naloxone label
Version not recorded · Effective date not recorded
In a neonatal study the mean plasma half-life was observed to be 3.1 ± 0.5 hours.
1.24 hours
- Numeric value
- 1.24
- Unit
- hours
- Source records
- 6
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 6 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:76b5a1ce-e601-457c-ab35-43533bba4394 (opens source in a new tab)
Naloxone label
Version not recorded · Effective date not recorded
1.85 (33% CV) hours and 2.08 (30% CV) hours; respectively, which was longer than that observed after administrations of a 0.4 mg naloxone hydrochloride intramuscular injection, where the half-life was 1.24 hours (26% CV).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:724df050-5332-4d0a-9a5f-17bf08a547e1 (opens source in a new tab)
Naloxone label
Version not recorded · Effective date not recorded
1.85 (33% CV) hours and 2.08 (30% CV) hours; respectively, which was longer than that observed after administrations of a 0.4 mg naloxone hydrochloride intramuscular injection, where the half-life was 1.24 hours (26% CV).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8d529b4c-85fd-4e50-9443-9080825307bf (opens source in a new tab)
Naloxone label
Version not recorded · Effective date not recorded
1.85 (33% CV) hours and 2.08 (30% CV) hours; respectively, which was longer than that observed after administrations of a 0.4 mg naloxone hydrochloride intramuscular injection, where the half-life was 1.24 hours (26% CV).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:139c30b9-5600-48f5-8610-0cacd2782398 (opens source in a new tab)
Naloxone label
Version not recorded · Effective date not recorded
1.85 (33% CV) hours and 2.08 (30% CV) hours; respectively, which was longer than that observed after administrations of a 0.4 mg naloxone hydrochloride intramuscular injection, where the half-life was 1.24 hours (26% CV).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0b3b5214-6f91-4bba-82d6-d57b16845df5 (opens source in a new tab)
Naloxone label
Version not recorded · Effective date not recorded
1.85 (33% CV) hours and 2.08 (30% CV) hours; respectively, which was longer than that observed after administrations of a 0.4 mg naloxone hydrochloride intramuscular injection, where the half-life was 1.24 hours (26% CV).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f8fcda15-8ba6-e66a-e053-6294a90a385c (opens source in a new tab)
Naloxone label
Version not recorded · Effective date not recorded
1.85 (33% CV) hours and 2.08 (30% CV) hours; respectively, which was longer than that observed after administrations of a 0.4 mg naloxone hydrochloride intramuscular injection, where the half-life was 1.24 hours (26% CV).
1.33 hours
- Numeric value
- 1.33
- Unit
- hours
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5bb502aa-014f-4a36-8972-42a9439168fe (opens source in a new tab)
Naloxone label
Version not recorded · Effective date not recorded
Elimination Following a single intranasal administration of REZENOPY nasal spray (10 mg dose of naloxone hydrochloride), the mean plasma half-life of naloxone in healthy adults was approximately 1.33 hours (16.09% CV) hours.
1.46 hours
- Numeric value
- 1.46
- Unit
- hours
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b5463553-b775-47a3-8d10-31e01ca1ec72 (opens source in a new tab)
Naloxone label
Version not recorded · Effective date not recorded
Elimination The mean plasma half-life of naloxone in healthy adults was 1.46 hours (14.1%CV) following a single administration of NALOXONE HYDROCHLORIDE injection.
1.50 hours
- Numeric value
- 1.5
- Unit
- hours
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:523c0909-bff6-4010-988a-53de18b7cb3f (opens source in a new tab)
Naloxone label
Version not recorded · Effective date not recorded
Elimination Following a single 5 mg/0.5 mL mg ZIMHI injection, the mean plasma half-life of naloxone in healthy adults was 1.50 hours with values for individual subjects ranging from 1.18 to 1.87 hours.
Projected row 1058
- Medicine slug
- naltrexone
- Compared field
- bioavailability
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 47
- Source count
- 45
- Agreement rate
- 0.822222
- Recorded readings
5 to 40%
- Numeric value
- 5
- Unit
- %
- Source records
- 37
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 37 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7976b328-ad8e-4208-9f61-19cd5ab5f36b (opens source in a new tab)
Naltrexone label
Version not recorded · Effective date not recorded
Although well absorbed orally, naltrexone is subject to significant first pass metabolism with oral bioavailability estimates ranging from 5 to 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a328c3e1-9132-491d-ae5b-45fd27ca4993 (opens source in a new tab)
Naltrexone label
Version not recorded · Effective date not recorded
Although well absorbed orally, naltrexone is subject to significant first pass metabolism with oral bioavailability estimates ranging from 5 to 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b773726e-1dc9-415a-81f3-32b43b61b9b1 (opens source in a new tab)
Naltrexone label
Version not recorded · Effective date not recorded
Although well absorbed orally, naltrexone is subject to significant first pass metabolism with oral bioavailability estimates ranging from 5 to 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f9807ec0-3504-4c66-8efe-ea25f84c782b (opens source in a new tab)
Naltrexone label
Version not recorded · Effective date not recorded
Although well absorbed orally, naltrexone is subject to significant first pass metabolism with oral bioavailability estimates ranging from 5 to 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d8433c5e-deb3-4f20-aaf6-9fed6bc44974 (opens source in a new tab)
Naltrexone label
Version not recorded · Effective date not recorded
Although well absorbed orally, naltrexone is subject to significant first pass metabolism with oral bioavailability estimates ranging from 5 to 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:49aa3d6d-2270-4615-aafa-b440859ab870 (opens source in a new tab)
Naltrexone label
Version not recorded · Effective date not recorded
Although well absorbed orally, naltrexone is subject to significant first pass metabolism with oral bioavailability estimates ranging from 5 to 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c67a22bb-d2bd-4da5-9d3e-6b5281f10891 (opens source in a new tab)
Naltrexone label
Version not recorded · Effective date not recorded
Although well absorbed orally, naltrexone is subject to significant first pass metabolism with oral bioavailability estimates ranging from 5 to 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:544f79a7-ca89-795d-e063-6294a90a8a97 (opens source in a new tab)
Naltrexone label
Version not recorded · Effective date not recorded
Although well absorbed orally, naltrexone is subject to significant first pass metabolism with oral bioavailability estimates ranging from 5 to 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:57439bad-00f0-5696-e063-6294a90a2ea5 (opens source in a new tab)
Naltrexone label
Version not recorded · Effective date not recorded
Although well absorbed orally, naltrexone is subject to significant first pass metabolism with oral bioavailability estimates ranging from 5 to 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:21b43dab-015c-c82f-ba6e-27da0ec12fc5 (opens source in a new tab)
Naltrexone label
Version not recorded · Effective date not recorded
Although well absorbed orally, naltrexone is subject to significant first pass metabolism with oral bioavailability estimates ranging from 5 to 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:db911559-26f5-43a0-b61f-3425176c936f (opens source in a new tab)
Naltrexone label
Version not recorded · Effective date not recorded
Although well absorbed orally, naltrexone is subject to significant first pass metabolism with oral bioavailability estimates ranging from 5 to 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:49b7b694-6fec-479b-be35-d03d816e13dd (opens source in a new tab)
Naltrexone label
Version not recorded · Effective date not recorded
Although well absorbed orally, naltrexone is subject to significant first pass metabolism with oral bioavailability estimates ranging from 5 to 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:00c04ff4-b6f2-466c-9ab9-813a60577db0 (opens source in a new tab)
Naltrexone label
Version not recorded · Effective date not recorded
Although well absorbed orally, naltrexone is subject to significant first pass metabolism with oral bioavailability estimates ranging from 5 to 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fa2f842f-001a-4f1e-8748-c7852579109c (opens source in a new tab)
Naltrexone label
Version not recorded · Effective date not recorded
Although well absorbed orally, naltrexone is subject to significant first pass metabolism with oral bioavailability estimates ranging from 5 to 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:60276f5c-657a-4b60-bcd0-44234903d7e0 (opens source in a new tab)
Naltrexone label
Version not recorded · Effective date not recorded
Although well absorbed orally, naltrexone is subject to significant first pass metabolism with oral bioavailability estimates ranging from 5 to 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d4d0537b-113a-4e49-bb50-bf5ddafe6b7d (opens source in a new tab)
Naltrexone label
Version not recorded · Effective date not recorded
Although well absorbed orally, naltrexone is subject to significant first pass metabolism with oral bioavailability estimates ranging from 5 to 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:69cb8573-08c1-4957-a768-6cd383f6a3f4 (opens source in a new tab)
Naltrexone label
Version not recorded · Effective date not recorded
Although well absorbed orally, naltrexone is subject to significant first pass metabolism with oral bioavailability estimates ranging from 5 to 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0f30f885-d0cd-4fa6-a8e0-142f08a56792 (opens source in a new tab)
Naltrexone label
Version not recorded · Effective date not recorded
Although well absorbed orally, naltrexone is subject to significant first pass metabolism with oral bioavailability estimates ranging from 5 to 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ab5b3829-96e5-4123-967a-29b41f13a4f7 (opens source in a new tab)
Naltrexone label
Version not recorded · Effective date not recorded
Although well absorbed orally, naltrexone is subject to significant first pass metabolism with oral bioavailability estimates ranging from 5 to 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f821dd49-3fa7-4d33-99de-19023ff1ae65 (opens source in a new tab)
Naltrexone label
Version not recorded · Effective date not recorded
Although well absorbed orally, naltrexone is subject to significant first pass metabolism with oral bioavailability estimates ranging from 5 to 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fdcfe000-09e0-44e4-8ebf-c52efb12ef60 (opens source in a new tab)
Naltrexone label
Version not recorded · Effective date not recorded
Although well absorbed orally, naltrexone is subject to significant first pass metabolism with oral bioavailability estimates ranging from 5 to 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:68cb0399-ca56-4310-8531-6b5552b71b25 (opens source in a new tab)
Naltrexone label
Version not recorded · Effective date not recorded
Although well absorbed orally, naltrexone is subject to significant first pass metabolism with oral bioavailability estimates ranging from 5 to 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b09b4b5e-795a-48e7-b7cc-2e29f41c5660 (opens source in a new tab)
Naltrexone label
Version not recorded · Effective date not recorded
Although well absorbed orally, naltrexone is subject to significant first pass metabolism with oral bioavailability estimates ranging from 5 to 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8f019ac1-13a8-42f2-bdb2-8aaef5896d96 (opens source in a new tab)
Naltrexone label
Version not recorded · Effective date not recorded
Although well absorbed orally, naltrexone is subject to significant first pass metabolism with oral bioavailability estimates ranging from 5 to 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b5d0b9d2-8d98-4800-855e-7e8054eadf68 (opens source in a new tab)
Naltrexone label
Version not recorded · Effective date not recorded
Although well absorbed orally, naltrexone is subject to significant first pass metabolism with oral bioavailability estimates ranging from 5 to 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fa0b0881-97f3-4ca2-bc15-0954293081db (opens source in a new tab)
Naltrexone label
Version not recorded · Effective date not recorded
Although well absorbed orally, naltrexone is subject to significant first pass metabolism with oral bioavailability estimates ranging from 5 to 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1e059495-5e64-0cb0-e063-6394a90a3ffc (opens source in a new tab)
Naltrexone label
Version not recorded · Effective date not recorded
Although well absorbed orally, naltrexone is subject to significant first pass metabolism with oral bioavailability estimates ranging from 5 to 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d7ba0156-6222-4619-a043-b5a1342d5375 (opens source in a new tab)
Naltrexone label
Version not recorded · Effective date not recorded
Although well absorbed orally, naltrexone is subject to significant first pass metabolism with oral bioavailability estimates ranging from 5 to 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:74087d2f-468d-4de1-a2fc-a489d0f2abef (opens source in a new tab)
Naltrexone label
Version not recorded · Effective date not recorded
Although well absorbed orally, naltrexone is subject to significant first pass metabolism with oral bioavailability estimates ranging from 5 to 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f3305f0b-fb9e-4009-b28f-47fe9b1b618b (opens source in a new tab)
Naltrexone label
Version not recorded · Effective date not recorded
Although well absorbed orally, naltrexone is subject to significant first pass metabolism with oral bioavailability estimates ranging from 5 to 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5fec6721-3611-44ec-b4b9-118472250b01 (opens source in a new tab)
Naltrexone label
Version not recorded · Effective date not recorded
Although well absorbed orally, naltrexone is subject to significant first pass metabolism with oral bioavailability estimates ranging from 5 to 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4f720879-1772-e734-e063-6394a90a0cf4 (opens source in a new tab)
Naltrexone label
Version not recorded · Effective date not recorded
Although well absorbed orally, naltrexone is subject to significant first pass metabolism with oral bioavailability estimates ranging from 5 to 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:adb7c4dc-221a-4d91-9687-0d78913a92ad (opens source in a new tab)
Naltrexone label
Version not recorded · Effective date not recorded
Although well absorbed orally, naltrexone is subject to significant first pass metabolism with oral bioavailability estimates ranging from 5 to 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:57e8b767-54c2-dfa3-e063-6394a90ae6c2 (opens source in a new tab)
Naltrexone label
Version not recorded · Effective date not recorded
Although well absorbed orally, naltrexone is subject to significant first pass metabolism with oral bioavailability estimates ranging from 5 to 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:637ed3da-476d-4f95-8bbc-f93eaa0aa57e (opens source in a new tab)
Naltrexone label
Version not recorded · Effective date not recorded
Although well absorbed orally, naltrexone is subject to significant first pass metabolism with oral bioavailability estimates ranging from 5 to 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5f188bdc-2009-43aa-ad32-f06dbfac2642 (opens source in a new tab)
Naltrexone label
Version not recorded · Effective date not recorded
Although well absorbed orally, naltrexone is subject to significant first pass metabolism with oral bioavailability estimates ranging from 5 to 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:56055980-d23b-ec7d-e063-6394a90a9cc2 (opens source in a new tab)
Naltrexone label
Version not recorded · Effective date not recorded
Although well absorbed orally, naltrexone is subject to significant first pass metabolism with oral bioavailability estimates ranging from 5 to 40%.
5%
- Numeric value
- 5
- Unit
- %
- Source records
- 8
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 8 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:06ff2d5a-e62b-4fa4-bbdb-01938535bc65 (opens source in a new tab)
Naltrexone label
Version not recorded · Effective date not recorded
Although well absorbed orally, naltrexone is subject to significant first pass metabolism with oral bioavailability estimates ranging from 5% to 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:43cd6961-4793-85ee-e063-6294a90ad772 (opens source in a new tab)
Naltrexone label
Version not recorded · Effective date not recorded
Although well absorbed orally, naltrexone is subject to significant first pass metabolism with oral bioavailability estimates ranging from 5% to 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:390bff41-7bab-b72a-e063-6294a90ad35d (opens source in a new tab)
Naltrexone label
Version not recorded · Effective date not recorded
Although well absorbed orally, naltrexone is subject to significant first pass metabolism with oral bioavailability estimates ranging from 5% to 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:10261f2f-e4c1-415c-b722-edeaab97a112 (opens source in a new tab)
Naltrexone label
Version not recorded · Effective date not recorded
Although well absorbed orally, naltrexone is subject to significant first pass metabolism with oral bioavailability estimates ranging from 5% to 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:838a1e88-1179-4a2a-a737-8ce008bb96a7 (opens source in a new tab)
Naltrexone label
Version not recorded · Effective date not recorded
Although well absorbed orally, naltrexone is subject to significant first pass metabolism with oral bioavailability estimates ranging from 5% to 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:81e25c6a-81b6-4cfb-91bf-be20c3ae546b (opens source in a new tab)
Naltrexone label
Version not recorded · Effective date not recorded
Although well absorbed orally, naltrexone is subject to significant first pass metabolism with oral bioavailability estimates ranging from 5% to 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0103a32b-14a9-48a8-8952-b2b12ef09649 (opens source in a new tab)
Naltrexone label
Version not recorded · Effective date not recorded
Although well absorbed orally, naltrexone is subject to significant first pass metabolism with oral bioavailability estimates ranging from 5% to 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3cbd0cad-7c56-ac0a-e063-6294a90a80e4 (opens source in a new tab)
Naltrexone label
Version not recorded · Effective date not recorded
Although well absorbed orally, naltrexone is subject to significant first pass metabolism with oral bioavailability estimates ranging from 5% to 40%.
Projected row 1059
- Medicine slug
- naltrexone
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 47
- Source count
- 45
- Agreement rate
- 1
- Recorded readings
4 hours
- Numeric value
- 4
- Unit
- hours
- Source records
- 45
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 45 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7976b328-ad8e-4208-9f61-19cd5ab5f36b (opens source in a new tab)
Naltrexone label
Version not recorded · Effective date not recorded
The mean elimination half-life (T-1/2) values for naltrexone and 6-β-naltrexol are 4 hours and 13 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a328c3e1-9132-491d-ae5b-45fd27ca4993 (opens source in a new tab)
Naltrexone label
Version not recorded · Effective date not recorded
The mean elimination half-life (T-1/2) values for naltrexone and 6-β-naltrexol are 4 hours and 13 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b773726e-1dc9-415a-81f3-32b43b61b9b1 (opens source in a new tab)
Naltrexone label
Version not recorded · Effective date not recorded
The mean elimination half-life (T-1/2) values for naltrexone and 6-β-naltrexol are 4 hours and 13 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f9807ec0-3504-4c66-8efe-ea25f84c782b (opens source in a new tab)
Naltrexone label
Version not recorded · Effective date not recorded
The mean elimination half-life (T-1/2) values for naltrexone and 6-ß-naltrexol are 4 hours and 13 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d8433c5e-deb3-4f20-aaf6-9fed6bc44974 (opens source in a new tab)
Naltrexone label
Version not recorded · Effective date not recorded
The mean elimination half-life (T-1/2) values for naltrexone and 6-β-naltrexol are 4 hours and 13 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:06ff2d5a-e62b-4fa4-bbdb-01938535bc65 (opens source in a new tab)
Naltrexone label
Version not recorded · Effective date not recorded
The mean elimination half-life (T-1/2) values for naltrexone and 6-β-naltrexol are 4 hours and 13 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:49aa3d6d-2270-4615-aafa-b440859ab870 (opens source in a new tab)
Naltrexone label
Version not recorded · Effective date not recorded
The mean elimination half-life (T 1/2 ) values for naltrexone and 6-β-naltrexol are 4 hours and 13 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c67a22bb-d2bd-4da5-9d3e-6b5281f10891 (opens source in a new tab)
Naltrexone label
Version not recorded · Effective date not recorded
The mean elimination half-life (T- 1/2 ) values for naltrexone and 6-ß-naltrexol are 4 hours and 13 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:544f79a7-ca89-795d-e063-6294a90a8a97 (opens source in a new tab)
Naltrexone label
Version not recorded · Effective date not recorded
The mean elimination half-life (T-1/2) values for naltrexone and 6-ß-naltrexol are 4 hours and 13 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:57439bad-00f0-5696-e063-6294a90a2ea5 (opens source in a new tab)
Naltrexone label
Version not recorded · Effective date not recorded
The mean elimination half-life (T 1/2 ) values for naltrexone and 6-β-naltrexol are 4 hours and 13 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:43cd6961-4793-85ee-e063-6294a90ad772 (opens source in a new tab)
Naltrexone label
Version not recorded · Effective date not recorded
The mean elimination half-life (T-1/2) values for naltrexone and 6-β-naltrexol are 4 hours and 13 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:390bff41-7bab-b72a-e063-6294a90ad35d (opens source in a new tab)
Naltrexone label
Version not recorded · Effective date not recorded
The mean elimination half-life (T-1/2) values for naltrexone and 6-β-naltrexol are 4 hours and 13 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:21b43dab-015c-c82f-ba6e-27da0ec12fc5 (opens source in a new tab)
Naltrexone label
Version not recorded · Effective date not recorded
The mean elimination half-life (T-1/2) values for naltrexone and 6-β-naltrexol are 4 hours and 13 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:db911559-26f5-43a0-b61f-3425176c936f (opens source in a new tab)
Naltrexone label
Version not recorded · Effective date not recorded
The mean elimination half-life (T-1/2) values for naltrexone and 6-ß-naltrexol are 4 hours and 13 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:10261f2f-e4c1-415c-b722-edeaab97a112 (opens source in a new tab)
Naltrexone label
Version not recorded · Effective date not recorded
The mean elimination half-life (T-1/2) values for naltrexone and 6-β-naltrexol are 4 hours and 13 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:49b7b694-6fec-479b-be35-d03d816e13dd (opens source in a new tab)
Naltrexone label
Version not recorded · Effective date not recorded
The mean elimination half-life (T-1/2) values for naltrexone and 6-ß-naltrexol are 4 hours and 13 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:838a1e88-1179-4a2a-a737-8ce008bb96a7 (opens source in a new tab)
Naltrexone label
Version not recorded · Effective date not recorded
The mean elimination half-life (T-1/2) values for naltrexone and 6-β-naltrexol are 4 hours and 13 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:00c04ff4-b6f2-466c-9ab9-813a60577db0 (opens source in a new tab)
Naltrexone label
Version not recorded · Effective date not recorded
The mean elimination half-life (T 1/2 ) values for naltrexone and 6-β-naltrexol are 4 hours and 13 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:81e25c6a-81b6-4cfb-91bf-be20c3ae546b (opens source in a new tab)
Naltrexone label
Version not recorded · Effective date not recorded
The mean elimination half-life (T-1/2) values for naltrexone and 6-β-naltrexol are 4 hours and 13 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fa2f842f-001a-4f1e-8748-c7852579109c (opens source in a new tab)
Naltrexone label
Version not recorded · Effective date not recorded
The mean elimination half-life (T-1/2) values for naltrexone and 6-ß-naltrexol are 4 hours and 13 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:60276f5c-657a-4b60-bcd0-44234903d7e0 (opens source in a new tab)
Naltrexone label
Version not recorded · Effective date not recorded
The mean elimination half-life (T-1/2) values for naltrexone and 6-β-naltrexol are 4 hours and 13 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d4d0537b-113a-4e49-bb50-bf5ddafe6b7d (opens source in a new tab)
Naltrexone label
Version not recorded · Effective date not recorded
The mean elimination half-life (T-1/2) values for naltrexone and 6-β-naltrexol are 4 hours and 13 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:69cb8573-08c1-4957-a768-6cd383f6a3f4 (opens source in a new tab)
Naltrexone label
Version not recorded · Effective date not recorded
The mean elimination half-life (T-1/2) values for naltrexone and 6-ß-naltrexol are 4 hours and 13 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0103a32b-14a9-48a8-8952-b2b12ef09649 (opens source in a new tab)
Naltrexone label
Version not recorded · Effective date not recorded
The mean elimination half-life (T-1/2) values for naltrexone and 6-β-naltrexol are 4 hours and 13 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0f30f885-d0cd-4fa6-a8e0-142f08a56792 (opens source in a new tab)
Naltrexone label
Version not recorded · Effective date not recorded
The mean elimination half-life (T-1/2) values for naltrexone and 6-ß-naltrexol are 4 hours and 13 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ab5b3829-96e5-4123-967a-29b41f13a4f7 (opens source in a new tab)
Naltrexone label
Version not recorded · Effective date not recorded
The mean elimination half-life (T-1/2) values for naltrexone and 6-β-naltrexol are 4 hours and 13 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f821dd49-3fa7-4d33-99de-19023ff1ae65 (opens source in a new tab)
Naltrexone label
Version not recorded · Effective date not recorded
The mean elimination half-life (T-1/2) values for naltrexone and 6-ß-naltrexol are 4 hours and 13 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fdcfe000-09e0-44e4-8ebf-c52efb12ef60 (opens source in a new tab)
Naltrexone label
Version not recorded · Effective date not recorded
The mean elimination half-life (T-1/2) values for naltrexone and 6-β-naltrexol are 4 hours and 13 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:68cb0399-ca56-4310-8531-6b5552b71b25 (opens source in a new tab)
Naltrexone label
Version not recorded · Effective date not recorded
The mean elimination half-life (T-1/2) values for naltrexone and 6-β-naltrexol are 4 hours and 13 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b09b4b5e-795a-48e7-b7cc-2e29f41c5660 (opens source in a new tab)
Naltrexone label
Version not recorded · Effective date not recorded
The mean elimination half-life (T-1/2) values for naltrexone and 6-β-naltrexol are 4 hours and 13 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8f019ac1-13a8-42f2-bdb2-8aaef5896d96 (opens source in a new tab)
Naltrexone label
Version not recorded · Effective date not recorded
The mean elimination half-life (T-1/2) values for naltrexone and 6-β-naltrexol are 4 hours and 13 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b5d0b9d2-8d98-4800-855e-7e8054eadf68 (opens source in a new tab)
Naltrexone label
Version not recorded · Effective date not recorded
The mean elimination half-life (T-1/2) values for naltrexone and 6-β-naltrexol are 4 hours and 13 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fa0b0881-97f3-4ca2-bc15-0954293081db (opens source in a new tab)
Naltrexone label
Version not recorded · Effective date not recorded
The mean elimination half-life (T 1/2 ) values for naltrexone and 6-β-naltrexol are 4 hours and 13 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1e059495-5e64-0cb0-e063-6394a90a3ffc (opens source in a new tab)
Naltrexone label
Version not recorded · Effective date not recorded
The mean elimination half-life (T-1/2) values for naltrexone and 6-β-naltrexol are 4 hours and 13 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d7ba0156-6222-4619-a043-b5a1342d5375 (opens source in a new tab)
Naltrexone label
Version not recorded · Effective date not recorded
The mean elimination half-life (T-1/2) values for naltrexone and 6-β-naltrexol are 4 hours and 13 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:74087d2f-468d-4de1-a2fc-a489d0f2abef (opens source in a new tab)
Naltrexone label
Version not recorded · Effective date not recorded
The mean elimination half-life (T-1/2) values for naltrexone and 6-β-naltrexol are 4 hours and 13 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f3305f0b-fb9e-4009-b28f-47fe9b1b618b (opens source in a new tab)
Naltrexone label
Version not recorded · Effective date not recorded
The mean elimination half-life (T-1/2) values for naltrexone and 6-ß-naltrexol are 4 hours and 13 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5fec6721-3611-44ec-b4b9-118472250b01 (opens source in a new tab)
Naltrexone label
Version not recorded · Effective date not recorded
The mean elimination half-life (T-1/2) values for naltrexone and 6-β-naltrexol are 4 hours and 13 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3cbd0cad-7c56-ac0a-e063-6294a90a80e4 (opens source in a new tab)
Naltrexone label
Version not recorded · Effective date not recorded
The mean elimination half-life (T-1/2) values for naltrexone and 6-β-naltrexol are 4 hours and 13 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4f720879-1772-e734-e063-6394a90a0cf4 (opens source in a new tab)
Naltrexone label
Version not recorded · Effective date not recorded
The mean elimination half-life (T-1/2) values for naltrexone and 6-β-naltrexol are 4 hours and 13 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:adb7c4dc-221a-4d91-9687-0d78913a92ad (opens source in a new tab)
Naltrexone label
Version not recorded · Effective date not recorded
The mean elimination half-life (T-1/2) values for naltrexone and 6-ß-naltrexol are 4 hours and 13 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:57e8b767-54c2-dfa3-e063-6394a90ae6c2 (opens source in a new tab)
Naltrexone label
Version not recorded · Effective date not recorded
The mean elimination half-life (T-1/2) values for naltrexone and 6-β-naltrexol are 4 hours and 13 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:637ed3da-476d-4f95-8bbc-f93eaa0aa57e (opens source in a new tab)
Naltrexone label
Version not recorded · Effective date not recorded
The mean elimination half-life (T-1/2) values for naltrexone and 6-β-naltrexol are 4 hours and 13 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5f188bdc-2009-43aa-ad32-f06dbfac2642 (opens source in a new tab)
Naltrexone label
Version not recorded · Effective date not recorded
The mean elimination half-life (T-1/2) values for naltrexone and 6-β-naltrexol are 4 hours and 13 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:56055980-d23b-ec7d-e063-6394a90a9cc2 (opens source in a new tab)
Naltrexone label
Version not recorded · Effective date not recorded
The mean elimination half-life (T-1/2) values for naltrexone and 6-β-naltrexol are 4 hours and 13 hours, respectively.
Projected row 1060
- Medicine slug
- naproxen
- Compared field
- bioavailability
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 387
- Source count
- 149
- Agreement rate
- 1
- Recorded readings
95%
- Numeric value
- 95
- Unit
- %
- Source records
- 149
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 149 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:37b264f9-b46d-4635-8fab-246b1e08b653 (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen sodium is rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1e406e47-408a-48cc-921e-52882a11581c (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen is rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fc3ee94a-adb7-411e-a662-2f2c6ddbabaf (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
Pharmacokinetics Naproxen is rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3e4e5371-d796-47c7-95c1-d99e82a0b282 (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
Pharmacokinetics Naproxen and naproxen sodium are rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1431b769-5535-78d6-e063-6394a90a8423 (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen is rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1fe9a6fc-940e-4a18-b3e9-b204fd67f263 (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen and naproxen sodium are rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1fdb4cbd-e9e8-47bb-b3d8-1f1ec8f411c8 (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen is rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:727913f6-9542-4a2d-9318-4b7ff521bffd (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen and naproxen sodium are rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6573681e-e9be-440f-a818-a533b744648e (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen and naproxen sodium are rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:86a3e612-3bfe-432f-9afd-972bb8a6644e (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen and naproxen sodium are rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2d01e583-670a-46f4-b5f2-3fad46d0376f (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen is rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0e7697ad-25c6-4405-9f9b-791633cb1ef7 (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen sodium is rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e0f430fd-4511-41c8-b5e9-894abe4f3c37 (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen and naproxen sodium are rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:307aa67f-53b9-4c60-a328-091bbf6338d4 (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen and naproxen sodium are rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0de6d673-fa76-e9c0-e063-6394a90a9ded (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen is rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4e97e645-552d-424b-990a-f94349a86f17 (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen and naproxen sodium are rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:000155a8-709c-44e5-a75f-cd890f3a7caf (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen and naproxen sodium are rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6bb65680-76ea-46e5-ae70-f3091e360368 (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen is rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:545fe39a-4777-b149-e063-6394a90a53cf (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen and naproxen sodium are rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e3a3e5d2-2d1e-74d3-e053-2995a90a82bf (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen is rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:24d44eb6-921e-4150-a6b2-81f42ced32ab (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen is rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:52503536-593e-808b-e063-6294a90a737f (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen is rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c136cf75-4ad4-8634-e053-2a95a90a53a4 (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen is rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:47d18804-d8d6-8248-e063-6394a90a48a9 (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen and naproxen sodium are rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9c963e77-6e05-47d0-a8d3-e581777377b9 (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen is rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d564f52d-171c-4e7d-974c-3a0e192e6c12 (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen is rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:21930f73-d3c2-4462-a487-74ed871b74b2 (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen and naproxen sodium are rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7fef9311-471b-472c-b4f2-c952a2b3a255 (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen is rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:124af155-0661-4054-9800-de547d8212d7 (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen is rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:205b1159-06e5-0d48-e063-6294a90acbd8 (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen and naproxen sodium are rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7c22a2d6-821c-4f83-aead-e756aed930e5 (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
49 - 77 60 6 49 - 74 C min (mcg/mL) 36 9 13 - 51 33 7 23 - 48 T max (hrs) 3 1 1 - 4 5 2 2-10 Absorption Naproxen itself is rapidly and completely absorbed from the GI tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:12202ef3-c65e-45a6-88ed-5d945d8fd41c (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen is rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:826fd9e3-22fe-408b-820c-f2b710189555 (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
60 6 49 to 74 C min (mcg/mL) 36 9 13 to 51 33 7 23 to 48 T max (hrs) 3 1 1 to 4 5 2 2 to 10 Absorption Naproxen itself is rapidly and completely absorbed from the GI tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1c5b2bc1-26bb-4f88-bded-399263c82331 (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen is rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d0670241-f1f9-4fdf-83d4-547e7b800811 (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen is rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:74134b90-d4c7-41bd-a1bd-2ac168db596f (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen is rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bce23087-f055-4234-b75d-69dd43233190 (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen and naproxen sodium are rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e2ed5556-8109-4002-bf8b-827518a84ea4 (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen and naproxen sodium are rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a5757b1a-62c9-4421-9794-6fb121ce9b7e (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen is rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2718e0b7-1ce6-457e-bee9-11b634dfd353 (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen and naproxen sodium are rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d2e5553a-7c90-407c-9f07-3be65560c23a (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
However, the interaction was more prominent after discontinuation of naproxen (washout) on day 11 [98.7% vs 84.3%] and did not normalize completely by day 13 [98.5% vs 90.7%]. [see Drug Interactions (7) ]. 12.3 Pharmacokinetic Naproxen and naproxen sodium are rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cfa88511-40bb-4658-b606-44c68d0746b7 (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen is rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e519fa49-5bd9-405c-a7fb-1403edb8976b (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen is rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:570974d4-0d5b-4df2-b307-37380511835d (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen is rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d06db628-f6f0-48e2-b538-69c0837c49e3 (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen and naproxen sodium are rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:852fed15-e78b-47a8-aeb4-623dfe1edad9 (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen is rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:52b8e52e-73be-3423-e063-6294a90af6e0 (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen and naproxen sodium are rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6c5bb008-e66f-4ef0-bf84-aca7eb5983e9 (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen and naproxen sodium are rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:29d98cf3-a0f2-3f89-e054-00144ff88e88 (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen and naproxen sodium are rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:af9ad850-57b5-a21d-e053-2a95a90ae68e (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
However, the interaction was more prominent after discontinuation of naproxen (washout) on day 11 [98.7% vs. 84.3%] and did not normalize completely by day 13 [98.5% vs. 90.7%] [see DRUG INTERACTIONS (7)]. 12.3 Pharmacokinetics Naproxen and naproxen sodium are rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:aa4d159c-9cbe-4d29-9532-33a312f1ae05 (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
Pharmacokinetics Naproxen and naproxen sodium are rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:313dd447-4b9f-4e5b-8ca9-4a2a5a1a53d9 (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
49 - 77 60 6 49 - 74 C min (mcg/mL) 36 9 13 - 51 33 7 23 - 48 T max (hrs) 3 1 1 - 4 5 2 2-10 Absorption Naproxen itself is rapidly and completely absorbed from the GI tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:af9a96cf-1cda-8ace-e053-2a95a90a18cc (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
However, the interaction was more prominent after discontinuation of naproxen (washout) on day 11 [98.7% vs. 84.3%] and did not normalize completely by day 13 [98.5% vs. 90.7%] [see DRUG INTERACTIONS (7)]. 12.3 Pharmacokinetics Naproxen and naproxen sodium are rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fd5e8d84-f92c-4f4b-ab0d-4cda7cf826bd (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen is rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b500bdba-946a-41ff-855c-1f2937547d01 (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen is rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9d28422f-6f25-4f14-9272-e0907c971f33 (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen and naproxen sodium are rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1a2b9a82-5b79-45ee-94ed-7a6f8c8b5170 (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen is rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2ae474dd-eaae-4401-8d42-613d672daea0 (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen is rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c43a43e2-e867-448d-8f59-3efc7c077cbc (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen and naproxen sodium are rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:43912294-77c9-eda8-e063-6394a90adf0a (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen is rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e64b3b36-f96e-463e-aca8-8f6e86724bcf (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen is rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f91c1a6b-b256-42e1-9da0-5f1975dec6ce (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen and naproxen sodium are rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a8b54258-84e7-41e8-9e51-137a3f442e6b (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen and naproxen sodium are rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3e8bcc59-dab1-1b4c-e054-00144ff88e88 (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
Pharmacokinetics Naproxen and naproxen sodium are rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:42f6a3a0-5a1e-40ca-8949-b8870dd95d2e (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen and naproxen sodium are rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1acfb8cc-6faf-4b3e-9304-4819c42de0a6 (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen is rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b8e417d2-3fc8-9a5e-e053-2a95a90a4155 (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen and naproxen sodium are rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f499a207-02c8-a338-e053-2995a90accc0 (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
However, the interaction was more prominent after discontinuation of naproxen (washout) on day 11 [98.7% vs 84.3%] and did not normalize completely by day 13 [98.5% vs 90.7%]. [ see DRUG INTERACTIONS (7)]. 12.3 Pharmacokinetics Naproxen is rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1c2325f7-1d65-429d-a64d-6ab075df1c20 (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen sodium is rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c986ba9a-6f48-8347-e053-2a95a90aa1c1 (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen is rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e3a4ab4a-b109-eb5e-e053-2a95a90afddd (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen is rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:79f48c92-783d-40f2-9865-89958a9f9de6 (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen and naproxen sodium are rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:37de42a6-701b-7f6e-e631-519e2ea78b54 (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen and naproxen sodium are rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e9eb8c40-85d9-4c8e-9523-a21d3591260f (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen and naproxen sodium are rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:369911ea-9069-9c45-e063-6394a90a5ce6 (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen and naproxen sodium are rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7e6f03fb-4b36-4418-9684-f45637abbb78 (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen is rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:96601d76-50ea-4dc0-b588-d174f8d8bb51 (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
Pharmacokinetics Naproxen and naproxen sodium are rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d801ba16-e2ec-4bb2-8cff-32388634b35a (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen and naproxen sodium are rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:12648efc-3be8-a915-e063-6394a90a3620 (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen is rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e2347581-90da-429a-b17c-cffd0039fb86 (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
Pharmacokinetics Naproxen is rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:985aedc1-8b3c-4cb4-af13-7203a2b57ab7 (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen is rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3375e139-d9de-8c2d-e063-6394a90a653d (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen and naproxen sodium are rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:129392c8-8ce1-4b78-8863-042db880095f (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen is rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8c3398bd-66b1-4a14-8aaa-e4a2d6749a08 (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen is rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b8a51c9a-488e-4377-a041-436f6a2f8893 (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
49 - 77 60 6 49 - 74 C min (mcg/mL) 36 9 13 - 51 33 7 23 - 48 T max (hrs) 3 1 1 - 4 5 2 2-10 Absorption Naproxen itself is rapidly and completely absorbed from the GI tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9225acaa-209f-958b-2c51-9a46995dec33 (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
49 - 77 60 6 49 - 74 C min (mcg/mL) 36 9 13 - 51 33 7 23 - 48 T max (hrs) 3 1 1 - 4 5 2 2-10 Absorption Naproxen itself is rapidly and completely absorbed from the GI tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:888efc91-b4de-4691-b84c-fb871e7a6dfe (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen is rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:49a00870-f580-4eb9-a95d-48fa956f147f (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen is rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f6f4a670-235e-4235-84a8-a74dc8ca5586 (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen and naproxen sodium are rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9f026fd5-f996-4383-b528-841d38d3dab5 (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen is rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2e72de28-e62b-44e0-b17d-500d13e0bcc6 (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen is rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4a05ca8c-1b03-fa86-e063-6394a90a4119 (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen and naproxen sodium are rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d292f376-1844-b01c-e053-2a95a90a0927 (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
However, the interaction was more prominent after discontinuation of naproxen (washout) on day 11 [98.7% vs 84.3%] and did not normalize completely by day 13 [98.5% vs 90.7%]. [ see DRUG INTERACTIONS (7)]. 12.3 Pharmacokinetics Naproxen is rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:50c52976-9e04-4a5e-9f21-aca3ea5c2924 (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen and naproxen sodium are rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:80233fa5-f8b4-42d5-a8c9-4a1d8fd4aba4 (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen and naproxen sodium are rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1cdcaba5-5550-40f6-94cc-b0a98cc17d3c (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen is rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:397db794-027c-4a89-993e-07c208b457a3 (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen sodium is rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:da61463f-f87b-4aba-b538-7264252cadb8 (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen and naproxen sodium are rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:af9aa7a0-e287-5935-e053-2995a90a1d11 (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
However, the interaction was more prominent after discontinuation of naproxen (washout) on day 11 [98.7% vs 84.3%] and did not normalize completely by day 13 [98.5% vs 90.7%] [see Drug Interactions (7)]. 12.3 Pharmacokinetics Naproxen and naproxen sodium are rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9d7bc470-fbba-40a6-a56c-f681a3cee9cf (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen and naproxen sodium are rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e63a034d-23ef-458f-88ed-8b6d73699621 (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen and naproxen sodium are rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c1cb9bb9-fbae-5e5c-e053-2995a90a0d21 (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen is rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:81e22c1f-f94d-46e9-8b7d-72dc2518319e (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen is rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f18181f4-6b14-48a8-a149-e45b3360a250 (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen is rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:181c2d5b-2c61-bf20-e063-6294a90a3f7f (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen and naproxen sodium are rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5a48c0d4-37bf-4c26-a9a7-5c67ff2adb4b (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen is rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c5c8b6fd-f3f5-4fed-823c-9a80386b27b1 (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen and naproxen sodium are rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ccd95dfc-9236-4707-a715-6a12c91519ff (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen is rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b0571e62-9330-438d-a2ba-873477f52dc4 (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen and naproxen sodium are rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bee7b482-8ba5-411d-90ee-de00df50d2b7 (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen and naproxen sodium are rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e633ff0b-eab7-f167-8d08-e9236e54042b (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
49 - 77 60 6 49 - 74 C min (mcg/mL) 36 9 13 - 51 33 7 23 - 48 T max (hrs) 3 1 1 - 4 5 2 2-10 Absorption Naproxen itself is rapidly and completely absorbed from the GI tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3e14f839-d1e4-44df-a457-29f005b3e62e (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen and naproxen sodium are rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:62a12771-bde9-4bc3-9ce9-672c8e31f020 (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
Pharmacokinetics Naproxen is rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:98efdeb8-ea38-456e-953f-ba589727f284 (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen is rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:af9a94a8-3825-eabd-e053-2a95a90acd58 (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
However, the interaction was more prominent after discontinuation of naproxen (washout) on day 11 [98.7% vs. 84.3%] and did not normalize completely by day 13 [98.5% vs. 90.7%] [see DRUG INTERACTIONS (7)]. 12.3 Pharmacokinetics Naproxen and naproxen sodium are rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:252726a7-757a-4b97-b5b8-ffff4ac1d103 (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen is rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0e5315bc-c02f-4749-be69-b5b528327d58 (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen and naproxen sodium are rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:46dbdb95-a0d0-4410-8d64-b22763b12af7 (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen is rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1f8da545-bcfe-4c22-a9f1-d34108120aa0 (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen is rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f2fb222a-b854-4e6f-9027-2e08aed24185 (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen is rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:67815abd-5e97-4ccb-ac9b-28c2ef6123e7 (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen is rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:97d6c4ef-13b1-4b0b-a15a-f0590019940d (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen is rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e06c2b43-9882-442e-8413-10d9a33aecb9 (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen is rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5954565a-d9bd-9e26-e063-6294a90a03cb (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen is rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:db478961-d984-7c8e-e053-2995a90a8a12 (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen is rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:145cdcc0-9bd5-4a0e-81fc-11a24d181980 (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen and naproxen sodium are rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a9549a47-3fa4-4a2b-95ac-b00e43aedae7 (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen is rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a90bfc07-d01e-427c-b2df-41bff7612d2f (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen and naproxen sodium are rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a5ea3a84-7acd-4f24-9f0f-9f871ce1b5f4 (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen and naproxen sodium are rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:46dd3908-6feb-4f50-e054-00144ff88e88 (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
Pharmacokinetics Naproxen and naproxen sodium are rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:af9ac948-4405-5abf-e053-2995a90af2b5 (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
However, the interaction was more prominent after discontinuation of naproxen (washout) on day 11 [98.7% vs 84.3%] and did not normalize completely by day 13 [98.5% vs 90.7%]. [see DRUG INTERACTIONS (7)]. 12.3 Pharmacokinetics Naproxen and naproxen sodium are rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:052e6fe3-d619-42c3-b64e-67c7aaf7271c (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen is rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6ae413ba-5a48-423f-8b8d-7a42661cf836 (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen and naproxen sodium are rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0041b483-34db-49a6-8665-f87e286cd0b8 (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen and naproxen sodium are rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:53e6519a-cb52-85e2-e063-6394a90abdcf (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen and naproxen sodium are rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c5e52ddd-a909-487a-bb46-01ad35690665 (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen and naproxen sodium are rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:88a548d1-97c0-46d0-825a-75ef689d6470 (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen and naproxen sodium are rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bbc61c0a-491a-4f50-a7bf-2ca94c771568 (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen is rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8181bb7a-d917-4388-bcb0-a74671b07b06 (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen and naproxen sodium are rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:83dd8829-7ba0-4a8d-a979-41a5e077c49f (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen and naproxen sodium are rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a4f31070-4ee1-4d64-8b1d-40b9011e124b (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen and naproxen sodium are rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:004bb832-29d5-add0-e063-6394a90a90f4 (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen is rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fa2fe6fd-c476-dd29-e053-6294a90a9e9e (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen is rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:87acd650-ea8a-4396-be72-5568c4b1755c (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen and naproxen sodium are rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fb07a76b-98ce-85dd-e053-6294a90aa6a8 (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen is rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:36996557-3227-b753-e063-6394a90a7b6f (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen and naproxen sodium are rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ab6ec2c9-5df9-346c-e053-2a95a90ac81d (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen and naproxen sodium are rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e6fbf8f1-b064-658d-17bb-e7d6320aa45f (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen and naproxen sodium are rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2794b60d-d09b-4115-9ff2-07ff15524e78 (opens source in a new tab)
Naproxen label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Naproxen and naproxen sodium are rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%.
Access
Query or download the projection
GET /api/datasets/source-consensus?limit=10&offset=1050Allowed query parameters
- q
- Case-insensitive text search over the public fields named for this dataset.
- state
- Exact comparability state.Values: agree, differ, not_comparable, insufficient_context
- field
- Exact recorded field key.Values: bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
- limit / offset
- Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.
Reuse and corrections
Keep the boundary attached
CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.
Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.